

- **Name:** Richard Finn, MD

- **Current Position:** Professor of Clinical Medicine, Department of Medicine, Division of Hematology/ Oncology, Geffen School of Medicine at UCLA, Director, Signal Transduction and Therapeutics Program. Jonsson Comprehensive Cancer Center at UCLA

- **Country:** UCLA

- **Educational Background:** MD, University of Southern California
BS, University of California, Los Angeles

- **Professional Experience:** Professor of Clinical Medicine, UCLA 2018-current
Associate Professor of Medicine, UCLA 2012-2018
Assistant Professor of Medicine, UCLA 2005-2012
Clinical Instructor of Medicine, UCLA 2003-2005

- **Professional Organizations:** ASCO, member
AACR, member

- **Main Scientific Publications:**
 1. **Finn RS**, Dering J, Conklin D, Kalous O, Cohen DJ, Desai A, Ginther C, Atefi M, Chen I, Fowst C, Los G, Slamon DJ. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. *Breast Cancer Res* 11(5):R77, 2009
 2. **Finn RS**, Crown, JP, Lang, I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Huang X, Kim ST, Randolph S, Slamon DJ. A Randomized Phase II study of Palbociclib (PD-0332991), Cyclin-Dependent Kinase (CDK) Inhibitor, in Combination with Letrozole Alone for First-line Treatment of Hormone Receptor –Positive, HER2-negative Advanced Breast Cancer (PALOMA-1/ TRIO 18) *Lancet Oncology* 2015 Jan;16(1):25-35.
 3. **Finn RS**, Martin M, Rugo S, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Dieras V, Slamon DJ. Palbociclib and Letrozole in Advanced Breast Cancer. *New England Journal of Medicine* 2016;375(20):1925-1936
 4. Kudo M, **Finn RS**, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. *Lancet*. 2018 Feb 9.
 5. **Finn RS**, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Gerolami R, Caparello C, Cabrera R, Chang C, Sun W, LeBerre MA, Baumhauer A, Meinhardt G, Bruix J. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. *J Hepatol*. 2018 Aug;69(2):353-358.